Selectis Health (OTCMKTS:GBCS – Get Free Report) and CareDx (NASDAQ:CDNA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations.
Volatility & Risk
Selectis Health has a beta of -1.07, meaning that its share price is 207% less volatile than the S&P 500. Comparatively, CareDx has a beta of 2.49, meaning that its share price is 149% more volatile than the S&P 500.
Valuation and Earnings
This table compares Selectis Health and CareDx”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Selectis Health | $41.44 million | 0.24 | -$1.02 million | ($0.34) | -9.41 |
| CareDx | $379.80 million | 3.41 | -$21.35 million | ($0.16) | -156.59 |
Selectis Health has higher earnings, but lower revenue than CareDx. CareDx is trading at a lower price-to-earnings ratio than Selectis Health, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Selectis Health and CareDx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Selectis Health | -2.45% | N/A | -3.03% |
| CareDx | -2.01% | -2.65% | -1.96% |
Analyst Recommendations
This is a breakdown of current recommendations for Selectis Health and CareDx, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Selectis Health | 0 | 0 | 0 | 0 | 0.00 |
| CareDx | 1 | 4 | 1 | 0 | 2.00 |
CareDx has a consensus price target of $25.00, suggesting a potential downside of 0.22%. Given CareDx’s stronger consensus rating and higher probable upside, analysts plainly believe CareDx is more favorable than Selectis Health.
Summary
CareDx beats Selectis Health on 9 of the 12 factors compared between the two stocks.
About Selectis Health
Selectis Health owns and/or operates healthcare facilities in Arkansas, Georgia, Ohio, and Oklahoma, providing a wide array of living services, speech, occupational, physical therapies, social services, and other rehabilitation and healthcare services. Selectis focuses on building strategic relationships with local communities in which its partnership can improve the quality of care for facility residents. With its focused growth strategy, Selectis intends to deepen its American Southcentral and Southeastern market presence to better serve the aging population along a full continuum of care.
About CareDx
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Receive News & Ratings for Selectis Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selectis Health and related companies with MarketBeat.com's FREE daily email newsletter.
